Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
- PMID: 37822504
- PMCID: PMC10562792
- DOI: 10.1016/j.isci.2023.107967
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Abstract
As SARS-CoV-2 becomes endemic, it is critical to understand immunity following early-life infection. We evaluated humoral responses to SARS-CoV-2 in 23 infants/young children. Antibody responses to SARS-CoV-2 spike antigens peaked approximately 30 days after infection and were maintained up to 500 days with little apparent decay. While the magnitude of humoral responses was similar to an adult cohort recovered from mild/moderate COVID-19, both binding and neutralization titers to WT SARS-CoV-2 were more durable in infants/young children, with spike and RBD IgG antibody half-life nearly 4X as long as in adults. IgG subtype analysis revealed that while IgG1 formed the majority of the response in both groups, IgG3 was more common in adults and IgG2 in infants/young children. These findings raise important questions regarding differential regulation of humoral immunity in infants/young children and adults and could have broad implications for the timing of vaccination and booster strategies in this age group.
Keywords: Clinical finding.
© 2023 The Author(s).
Conflict of interest statement
M.S.S. has served as an advisor for Ocugen and Moderna. E.J.A. has consulted for Pfizer, Sanofi Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sonfi-Pasteur, Janssen, and Micron. He also serves on data and safety monitoring boards for Kentucky BioProcessing, Inc., and Sanofi Pasteur. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. M.A.S. received funding from CDC, Pfizer, Merck, and Cepheid to study immune response to respiratory virus infections and vaccinations.
Figures
Update of
-
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults.medRxiv [Preprint]. 2023 Apr 11:2023.04.10.23288360. doi: 10.1101/2023.04.10.23288360. medRxiv. 2023. Update in: iScience. 2023 Sep 20;26(10):107967. doi: 10.1016/j.isci.2023.107967. PMID: 37090559 Free PMC article. Updated. Preprint.
References
-
- Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., COVID-19 Genomics UK Consortium. Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., Robertson D.L. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7. - DOI - PMC - PubMed
-
- Mantus G., Nyhoff L.E., Edara V.V., Zarnitsyna V.I., Ciric C.R., Flowers M.W., Norwood C., Ellis M., Hussaini L., Manning K.E., et al. Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell Rep. Med. 2022;3:100603. doi: 10.1016/j.xcrm.2022.100603. - DOI - PMC - PubMed
-
- Cohen K.W., Linderman S.L., Moodie Z., Czartoski J., Lai L., Mantus G., Norwood C., Nyhoff L.E., Edara V.V., Floyd K., et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2021;2:100354. doi: 10.1016/j.xcrm.2021.100354. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
